---
document_datetime: 2025-12-02 04:52:37
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/evusheld.html
document_name: evusheld.html
version: success
processing_time: 0.113678
conversion_datetime: 2025-12-28 00:30:19.192994
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Evusheld

[RSS](/en/individual-human-medicine.xml/67565)

##### Withdrawn

This medicine's authorisation has been withdrawn

tixagevimab / cilgavimab Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Evusheld](#news-on)
- [Related content](#related-content-72350)
- [More information on Evusheld](#related-medicines)

- Rolling review
- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 12 September 2025, the European Commission withdrew the marketing authorisation for Evusheld (tixagevimab / cilgavimab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, AstraZeneca AB, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Evusheld was granted marketing authorisation in the EU on 25 March 2022 for pre-exposure prophylaxis and treatment of COVID-19. The marketing authorisation was initially valid for a 5-year period.

Evusheld : EPAR - Medicine overview

Reference Number: EMA/173193/2022

English (EN) (127.24 KB - PDF)

**First published:** 30/03/2022

**Last updated:** 14/10/2025

[View](/en/documents/overview/evusheld-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-781)

български (BG) (157.43 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/bg/documents/overview/evusheld-epar-medicine-overview_bg.pdf)

español (ES) (127.7 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/es/documents/overview/evusheld-epar-medicine-overview_es.pdf)

čeština (CS) (152.61 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/cs/documents/overview/evusheld-epar-medicine-overview_cs.pdf)

dansk (DA) (127.8 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/da/documents/overview/evusheld-epar-medicine-overview_da.pdf)

Deutsch (DE) (131.19 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/de/documents/overview/evusheld-epar-medicine-overview_de.pdf)

eesti keel (ET) (113.82 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/et/documents/overview/evusheld-epar-medicine-overview_et.pdf)

ελληνικά (EL) (160.11 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/el/documents/overview/evusheld-epar-medicine-overview_el.pdf)

français (FR) (128.4 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/fr/documents/overview/evusheld-epar-medicine-overview_fr.pdf)

hrvatski (HR) (152.68 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/hr/documents/overview/evusheld-epar-medicine-overview_hr.pdf)

italiano (IT) (126.63 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/it/documents/overview/evusheld-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (160.37 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/lv/documents/overview/evusheld-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (150.13 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/lt/documents/overview/evusheld-epar-medicine-overview_lt.pdf)

magyar (HU) (152 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/hu/documents/overview/evusheld-epar-medicine-overview_hu.pdf)

Malti (MT) (152.23 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/mt/documents/overview/evusheld-epar-medicine-overview_mt.pdf)

Nederlands (NL) (129.03 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/nl/documents/overview/evusheld-epar-medicine-overview_nl.pdf)

polski (PL) (154.55 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/pl/documents/overview/evusheld-epar-medicine-overview_pl.pdf)

português (PT) (128.4 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/pt/documents/overview/evusheld-epar-medicine-overview_pt.pdf)

română (RO) (148.63 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/ro/documents/overview/evusheld-epar-medicine-overview_ro.pdf)

slovenčina (SK) (151.99 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/sk/documents/overview/evusheld-epar-medicine-overview_sk.pdf)

slovenščina (SL) (148.55 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/sl/documents/overview/evusheld-epar-medicine-overview_sl.pdf)

Suomi (FI) (124.99 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/fi/documents/overview/evusheld-epar-medicine-overview_fi.pdf)

svenska (SV) (125.52 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/sv/documents/overview/evusheld-epar-medicine-overview_sv.pdf)

Evusheld : EPAR - Risk-management-plan

English (EN) (881.12 KB - PDF)

**First published:** 05/05/2022

**Last updated:** 14/10/2025

[View](/en/documents/rmp/evusheld-epar-risk-management-plan_en.pdf)

## Product information

Evusheld : EPAR - Product information

English (EN) (436.19 KB - PDF)

**First published:** 30/03/2022

**Last updated:** 14/10/2025

[View](/en/documents/product-information/evusheld-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-779)

български (BG) (536.36 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/bg/documents/product-information/evusheld-epar-product-information_bg.pdf)

español (ES) (423.81 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/es/documents/product-information/evusheld-epar-product-information_es.pdf)

čeština (CS) (483.88 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/cs/documents/product-information/evusheld-epar-product-information_cs.pdf)

dansk (DA) (408.41 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/da/documents/product-information/evusheld-epar-product-information_da.pdf)

Deutsch (DE) (434.75 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/de/documents/product-information/evusheld-epar-product-information_de.pdf)

eesti keel (ET) (390.56 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/et/documents/product-information/evusheld-epar-product-information_et.pdf)

ελληνικά (EL) (529.17 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/el/documents/product-information/evusheld-epar-product-information_el.pdf)

français (FR) (448.85 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/fr/documents/product-information/evusheld-epar-product-information_fr.pdf)

hrvatski (HR) (444.38 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/hr/documents/product-information/evusheld-epar-product-information_hr.pdf)

íslenska (IS) (440.97 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/is/documents/product-information/evusheld-epar-product-information_is.pdf)

italiano (IT) (434.2 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/it/documents/product-information/evusheld-epar-product-information_it.pdf)

latviešu valoda (LV) (491.1 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/lv/documents/product-information/evusheld-epar-product-information_lv.pdf)

lietuvių kalba (LT) (450.53 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/lt/documents/product-information/evusheld-epar-product-information_lt.pdf)

magyar (HU) (600.86 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/hu/documents/product-information/evusheld-epar-product-information_hu.pdf)

Malti (MT) (489.18 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/mt/documents/product-information/evusheld-epar-product-information_mt.pdf)

Nederlands (NL) (471.36 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/nl/documents/product-information/evusheld-epar-product-information_nl.pdf)

norsk (NO) (424.16 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/no/documents/product-information/evusheld-epar-product-information_no.pdf)

polski (PL) (546.58 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/pl/documents/product-information/evusheld-epar-product-information_pl.pdf)

português (PT) (421.31 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/pt/documents/product-information/evusheld-epar-product-information_pt.pdf)

română (RO) (465.6 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/ro/documents/product-information/evusheld-epar-product-information_ro.pdf)

slovenčina (SK) (510.04 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/sk/documents/product-information/evusheld-epar-product-information_sk.pdf)

slovenščina (SL) (493.71 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/sl/documents/product-information/evusheld-epar-product-information_sl.pdf)

Suomi (FI) (411.23 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/fi/documents/product-information/evusheld-epar-product-information_fi.pdf)

svenska (SV) (428.17 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/sv/documents/product-information/evusheld-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0019 11/10/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Evusheld : EPAR - All authorised presentations

English (EN) (46.41 KB - PDF)

**First published:** 30/03/2022

**Last updated:** 14/10/2025

[View](/en/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-574)

български (BG) (51.09 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/bg/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_bg.pdf)

español (ES) (46.45 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/es/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_es.pdf)

čeština (CS) (47.01 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/cs/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (47.94 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/da/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (48.27 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/de/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (45.61 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/et/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (50.32 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/el/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_el.pdf)

français (FR) (46.19 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/fr/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (46.7 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/hr/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (69.83 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/is/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_is.pdf)

italiano (IT) (45.94 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/it/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (47.52 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/lv/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (56.83 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/lt/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (47.55 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/hu/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (47.28 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/mt/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (46.85 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/nl/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (47.57 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/no/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_no.pdf)

polski (PL) (48.33 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/pl/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_pl.pdf)

português (PT) (47.51 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/pt/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_pt.pdf)

română (RO) (46.56 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/ro/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (47.73 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/sk/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (46.4 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/sl/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (66.19 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/fi/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (46.14 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

14/10/2025

[View](/sv/documents/all-authorised-presentations/evusheld-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Evusheld Active substance

- tixagevimab
- cilgavimab

International non-proprietary name (INN) or common name

- tixagevimab
- cilgavimab

Therapeutic area (MeSH) COVID-19 virus infection

### Therapeutic indication

Prevention of COVID-19.

## Authorisation details

EMA product number EMEA/H/C/005788 Marketing authorisation holder

AstraZeneca AB

151 85 Sodertalje

Opinion adopted 24/03/2022 Marketing authorisation issued 25/03/2022 Withdrawal of marketing authorisation 12/09/2025 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Evusheld : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (159.67 KB - PDF)

**First published:** 26/09/2022

**Last updated:** 14/10/2025

[View](/en/documents/procedural-steps-after/evusheld-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Evusheld-H-C-5788-P46-024 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/56406/2025

English (EN) (1.44 MB - PDF)

**First published:** 12/03/2025

**Last updated:** 14/10/2025

[View](/en/documents/variation-report/evusheld-h-c-5788-p46-024-epar-assessment-report-variation_en.pdf)

Evusheld-H-C-PSUSA-00010992-202211 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/374564/2023

English (EN) (135.93 KB - PDF)

**First published:** 18/08/2023

**Last updated:** 14/10/2025

[View](/en/documents/scientific-conclusion/evusheld-h-c-psusa-00010992-202211-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

Evusheld : EPAR - Assessment report - variation

Adopted

Reference Number: EMA/834036/2022

English (EN) (10.08 MB - PDF)

**First published:** 16/11/2022

**Last updated:** 14/10/2025

[View](/en/documents/variation-report/evusheld-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Evusheld (II-01)

Adopted

Reference Number: EMA/759875/2022

English (EN) (156.63 KB - PDF)

**First published:** 16/09/2022

**Last updated:** 14/10/2025

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-evusheld-ii-01_en.pdf)

## Initial marketing authorisation documents

Evusheld : EPAR - Public assessment report

Adopted

Reference Number: EMA/205600/2022

English (EN) (9.41 MB - PDF)

**First published:** 28/04/2022

**Last updated:** 14/10/2025

[View](/en/documents/assessment-report/evusheld-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Evusheld

Adopted

Reference Number: EMA/184295/2022

English (EN) (140.41 KB - PDF)

**First published:** 25/03/2022

**Last updated:** 14/10/2025

[View](/en/documents/smop-initial/chmp-summary-opinion-evusheld_en.pdf)

#### News on Evusheld

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2024) 13/12/2024

[ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-2](/en/news/etf-warns-monoclonal-antibodies-may-not-be-effective-against-emerging-strains-sars-cov-2) 09/12/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022) 16/09/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 March 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-march-2022) 25/03/2022

[EMA recommends authorisation of COVID-19 medicine Evusheld](/en/news/ema-recommends-authorisation-covid-19-medicine-evusheld) 24/03/2022

[EMA starts rolling review of Evusheld (tixagevimab and cilgavimab)](/en/news/ema-starts-rolling-review-evusheld-tixagevimab-cilgavimab) 14/10/2021

#### Related content

- [Emergency Task Force (ETF) documents: COVID-19](/en/committees/working-parties-other-groups/emergency-task-force-etf/emergency-task-force-etf-recommendations#covid-19-66890)

#### More information on Evusheld

- [EMEA-002900-PIP01-20-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002900-pip01-20-m02)
- [EMEA-002925-PIP01-20-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002925-pip01-20-m02)
- [EMEA-003079-PIP01-22 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-003079-pip01-22)

**This page was last updated on** 14/10/2025

## Share this page

[Back to top](#main-content)